## Treatment of Severe Malaria (Cerebral Malaria + Shock) **Key Point:** Artemether is the WHO-recommended and Indian guideline-endorsed first-line drug for severe malaria, including cerebral malaria with shock. ### Severity Criteria Met in This Case 1. **Cerebral malaria**: Altered mental status (confusion, GCS 12) + seizures 2. **Shock**: Hypotension (90/60 mmHg) 3. **High parasitemia**: 8% (≥5% indicates severe malaria) 4. **P. falciparum**: Most likely to cause severe disease ### Artemether: First-Line for Severe Malaria | Feature | Artemether | |---------|------------| | **Route** | Intramuscular or intravenous | | **Dose** | 3.2 mg/kg at 0, 24, 48 hrs, then daily | | **Onset** | Rapid (< 1 hour) | | **Efficacy** | 90% reduction in mortality vs. quinine | | **CNS penetration** | Excellent; crosses blood–brain barrier | | **Shock management** | Compatible with vasopressors | ### Why Artemether Over Quinine? **High-Yield:** SEAQUAMAT and AQUAMAT trials (Lancet 2011) demonstrated artemether superior to quinine in severe malaria: - **Mortality reduction**: 35% lower with artemether - **Neurological complications**: Fewer seizures and coma duration - **Safety**: Better tolerability; no ototoxicity risk ### Clinical Pearl In severe malaria, parenteral therapy is mandatory. Artemether is now the global standard; quinine is a second-line alternative only if artemether unavailable. This patient requires ICU admission, supportive care (fluids, vasopressors for shock, anticonvulsants), and artemether immediately. ### Post-Artemether Transition Once patient improves and can tolerate oral intake → switch to artemisinin-based combination therapy (ACT) such as artemether–lumefantrine or artesunate–amodiaquine to complete 3-day course. [cite:Harrison 21e Ch 219; WHO Guidelines 2021]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.